Date: 2011-12-09
Type of information: Collaboration agreement
Compound: HercepTest® and HER2 FISH pharmDx® as companion diagnostics for pertuzumab
Company: Dako (Denmark) Genentech a member of the Roche Group (USA-Switzerland)
Therapeutic area: Cancer Oncology
Type agreement: collaboration
Action mechanism:
Disease: advanced HER2-positive breast cancer
Details: Dako has signed an agreement with Genentech, a member of the Roche Group, to collaborate on the regulatory submissions of Dako's HercepTest® and HER2 FISH pharmDx® as companion diagnostics for a Genentech investigational drug candidate, pertuzumab, in patients with advanced HER2-positive breast cancer. Under the terms of the agreement, Dako and Genentech will collaborate on the regulatory submissions for HercepTest® and HER2 FISH pharmDx® in the US market to identify cancer patients who may be eligible for pertuzumab.
The collaboration on the joint submission process for HercepTest® and HER2 FISH pharmDx® as companion diagnostics for pertuzumab is in line with Dako's ongoing strategy to combine its strengths with pharmaceutical companies to grow the offering of Dako's companion diagnostic assays.
Financial terms: Financial details were not disclosed.
Latest news: